Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jul 20;7(7):e015099.
doi: 10.1136/bmjopen-2016-015099.

A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial

Dipak Kotecha  1   2   3   4 , Melanie Calvert  4   5 , Jonathan J Deeks  5   6 , Michael Griffith  2 , Paulus Kirchhof  1   2   3   4 , Gregory Yh Lip  1   3   4 , Samir Mehta  6 , Gemma Slinn  6 , Mary Stanbury  7 , Richard P Steeds  1   2 , Jonathan N Townend  1   2
Affiliations
Clinical Trial

A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial

Dipak Kotecha et al. BMJ Open. .

Abstract

Background and objective: Atrial fibrillation (AF) is common and causes impaired quality of life, an increased risk of stroke and death as well as frequent hospital admissions. The majority of patients with AF require control of heart rate. In this article , we summarise the limited evidence from clinical trials that guides prescription, and present the rationale and protocol for a new randomised trial. As rate control has not yet been shown to reduce mortality, there is a clear need to compare the impact of therapy on quality of life, cardiac function and exercise capacity. Such a trial should concentrate on the long-term effects of treatment in the largest proportion of patients with AF, those with symptomatic permanent AF, with the aim of improving patient well-being.

Design and intervention: The RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) trial will enrol 160 participants with a prospective, randomised, open-label, blinded end point design comparing initial rate control with digoxin or bisoprolol. This will be the first head-to-head randomised trial of digoxin and beta-blockers in AF.

Participants: Recruited patients will be aged ≥60 years with permanent AF and symptoms of breathlessness (equivalent to New York Heart Association class II or above), with few exclusion criteria to maximise generalisability to routine clinical practice.

Outcome measures: The primary outcome is patient-reported quality of life, with secondary outcomes including echocardiographic ventricular function, exercise capacity and biomarkers of cellular and clinical response. Follow-up will occur at 6 and 12 months, with feasibility components to inform the design of a future trial powered to detect a difference in hospital admission. The RATE-AF trial will underpin an integrated approach to management including biomarkers, functions and symptoms that will guide future research into optimal, personalised rate control in patients with AF.

Ethics and dissemination: East Midlands-Derby Research Ethics Committee (16/EM/0178); peer-reviewed publications.

Trial registration: Clinicaltrials.gov: NCT02391337; ISRCTN: 95259705. Pre-results.

Keywords: Echocardiography; Protocols & guidelines; RATE-AF; atrial fibrillation; heart rate; quality of life.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None of the authors report a conflict of interest. All authors have completed the ICMJE uniform disclosure form (www.icmje.org/coi_disclosure.pdf) and declare: DK reports grants from Menarini, during the conduct of the study; non-financial support from Daiichi Sankyo and personal fees from AtriCure, outside the submitted work. MC reports grants from the National Institute of Health Research, during the conduct of the study; and personal fees from Astella Pharma and Ferring Pharma, outside the submitted work. PK reports consulting fees and honoraria from Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Pfizer and Servier, all outside the submitted work; research grants from Bristol-Myers Squibb, Pfizer, Cardiovascular Therapeutics, Daiichi Sankyo, Sanofi, St. Jude Medical, German Federal Ministry for Education and Research (BMBF), Fondation Leducq, German Research Foundation (DFG), European Union, British Heart Foundation and Medical Research Council UK, all outside the submitted work; and is listed on two patent applications on AF therapy and markers for AF, both outside the submitted work. GYHL has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Biotronik, Portola and Boehringer Ingelheim, and has been on the speaker’s bureau for Bayer, BMS/Pfizer, Boehringer Ingelheim and Sanofi Aventis. RPS is the President of the British Society of Echocardiography. JJD, MG, MS. JNT, SM, GS report no competing interests.

Figures

Figure 1
Figure 1
Evidence-based summary for management of atrial fibrillation. Summary of evidence for main components of clinical management, highlighting paucity of robust data for key issues regarding rate control therapy. RCT, randomised controlled trial; LV, left ventricular; NOAC, novel oral anticoagulants.
Figure 2
Figure 2
Hospitalisation in rate vs rhythm control trials. Meta-analysis of hospitalisation in the six largest rate vs rhythm control trials, excluding hospital visits for cardioversion procedures, where applicable. Studies are pooled with a random-effects model. Significant heterogeneity was identified, with an I value of 66.8% (p=0.01). Grey boxes represent the comparative weight of the study. STAF, Strategies of Treatment of Atrial Fibrillation study (cardioversion/AAD vs rate control in persistent AF); PIAF, Pharmacological Intervention in Atrial Fibrillation trial (amiodarone/cardioversion vs diltiazem in persistent AF); HOT CAFE, How to Treat Chronic Atrial Fibrillation study (cardioversion/AAD vs rate control in persistent AF); AF-CHF, Atrial Fibrillation and Congestive Heart Failure trial (cardioversion/AAD vs rate control in paroxysmal/persistent AF with LVEF ≤35%); CRAAFT, Control of Rate vs Rhythm in rheumatic Atrial Fibrillation Trial (cardioversion/amiodarone vs diltiazem in persistent AF due to rheumatic heart disease); AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management study (AAD/cardioversion versus rate control in paroxysmal/persistent AF); AAD, anti-arrhythmic drugs; LVEF, left-ventricular ejection fraction.
Figure 3
Figure 3
The  RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) trial schema. Trial flow chart, including major end points and inclusion/exclusion criteria.
See this image and copyright information in PMC

References

    1. Kirchhof P, Benussi S, Kotecha D, et al. . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962.10.1093/eurheartj/ehw210 - DOI - PubMed
    1. Chugh SS, Havmoeller R, Narayanan K, et al. . Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837–47.10.1161/CIRCULATIONAHA.113.005119 - DOI - PMC - PubMed
    1. Krijthe BP, Kunst A, Benjamin EJ, et al. . Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013;34:2746–51.10.1093/eurheartj/eht280 - DOI - PMC - PubMed
    1. Lane DA, Skjøth F, Lip GYH, et al. . Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. J Am Heart Assoc 2017;6:e00515510.1161/JAHA.116.005155 - DOI - PMC - PubMed
    1. Chiang CE, Naditch-Brûlé L, Murin J, et al. . Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5:632–9.10.1161/CIRCEP.112.970749 - DOI - PubMed

Publication types

MeSH terms

Associated data